{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:40Z","timestamp":1790963620847,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":78,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81,974,005"],"award-info":[{"award-number":["81,974,005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-SYBLD2022MS-0055"],"award-info":[{"award-number":["Y-SYBLD2022MS-0055"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.ctarc.2025.100902","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T03:03:59Z","timestamp":1743476639000},"page":"100902","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis"],"prefix":"10.1016","volume":"43","author":[{"given":"Jinhuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fankai","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-7209","authenticated-orcid":false,"given":"Miao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2025.100902_bib0001","article-title":"A deep insight into CAR-T cell therapy in non-hodgkin lymphoma: application, opportunities, and future directions [retracted in: front Immunol. 2023 Sep 04;14:1285110]","volume":"12","author":"Marofi","year":"2021","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.ctarc.2025.100902_bib0002","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? [published correction appears in Blood. 2023 Feb 9;141(6):683]","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2025.100902_bib0003","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100902_bib0004","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2025.100902_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2025.100902_bib0006","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA- 12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100902_bib0007","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.21037\/tcr-20-72","article-title":"Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy","volume":"9","author":"Yang","year":"2020","journal-title":"Transl. Cancer Res."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100902_bib0008","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/s41409-021-01420-9","article-title":"Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"56","author":"Mohty","year":"2021","journal-title":"Bone Marrow TransPlant"},{"issue":"4","key":"10.1016\/j.ctarc.2025.100902_bib0009","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000510768","article-title":"Current treatment of refractory\/relapsed chronic lymphocytic leukemia: a focus on novel drugs","volume":"144","author":"Smolewski","year":"2021","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100902_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","article-title":"Second-generation inhibitors of Bruton tyrosine kinase","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2025.100902_bib0011","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of bruton's tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100902_bib0012","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/fon-2019-0844","article-title":"ALPINE: zanubrutinib versus ibrutinib in relapsed \/refractory chronic lymphocytic leukemia \/small lymphocytic lymphoma","volume":"16","author":"Hillmen","year":"2020","journal-title":"Future Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100902_bib0013","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.220590","article-title":"Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma","volume":"105","author":"Flinsenberg","year":"2020","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.ctarc.2025.100902_bib0014","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomised phase 3 trial of zanubrutinib versus ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2025.100902_bib0015","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1182\/bloodadvances.2020003698","article-title":"Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large b-cell lymphoma","volume":"6","author":"Yang","year":"2022","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100902_bib0016","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jcyt.2023.03.005","article-title":"Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma","volume":"25","author":"Luo","year":"2023","journal-title":"Cytotherapy."},{"key":"10.1016\/j.ctarc.2025.100902_bib0017","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/hon.2672","article-title":"Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia","volume":"37","author":"Ma","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.ctarc.2025.100902_bib0018","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.21037\/atm-20-4363","article-title":"Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed\/refractory B-cell lymphoma: a single-center study","volume":"8","author":"Huang","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ctarc.2025.100902_bib0019","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN Guidelines insights: b-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"2","key":"10.1016\/j.ctarc.2025.100902_bib0020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ctarc.2025.100902_bib0021","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow TransPlant"},{"issue":"5","key":"10.1016\/j.ctarc.2025.100902_bib0022","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jmoldx.2020.02.007","article-title":"Detection and quantification of chimeric antigen receptor transgene copy number by droplet digital pcr versus real-time pcr","volume":"22","author":"Lou","year":"2020","journal-title":"J. Mol. Diagn."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100902_bib0023","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/ejh.13851","article-title":"CAR-T cell therapy for patients with hematological malignancies. A systematic review","volume":"109","author":"Pasqui","year":"2022","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100902_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr. Probl. Cancer"},{"issue":"7277","key":"10.1016\/j.ctarc.2025.100902_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B- cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctarc.2025.100902_bib0026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1): a single- arm, multicentre, phase 1- 2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2025.100902_bib0027","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long- term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B- cell lymphomas (JULIET): a multicentre, open- label, single- arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2025.100902_bib0028","article-title":"CD19\/CD22 Chimeric antigen receptor T cell cocktail therapy following autologous transplantation in patients with relapsed\/refractory aggressive B cell lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"TransPlant Cell Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100902_bib0029","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-022-00924-0","article-title":"Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT","volume":"7","author":"Wei","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.ctarc.2025.100902_bib0030","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41408-021-00523-2","article-title":"Sequential CD19\/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma","volume":"11","author":"Wu","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.ctarc.2025.100902_bib0031","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s40164-022-00315-9","article-title":"Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect","volume":"11","author":"Wang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2025.100902_bib0032","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2217\/imt.14.44","article-title":"Cancer CARtography: charting out a new approach to cancer immunotherapy","volume":"6","author":"Patel","year":"2014","journal-title":"Immunotherapy."},{"key":"10.1016\/j.ctarc.2025.100902_bib0033","first-page":"731","article-title":"CART cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"GiavridisT","year":"2018","journal-title":"NatMed"},{"key":"10.1016\/j.ctarc.2025.100902_bib0034","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CART cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294225000401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T18:57:21Z","timestamp":1762628241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294225000401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"alternative-id":["S2468294225000401"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100902","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2025.100902","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100902"}}